EuroPCR 24: Ancillary SMART Trial Analyses

Published: 21 May 2024

  • Views:

    Views Icon 254
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) joins us to discuss the findings from an ancillary analysis of the SMART trial (NCT04722250).

The SMART trial is a prospective, multi-center, randomized controlled study that aims to investigate the valve safety and performance of self expanding as compared to balloon-expandable transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli and severe symptomatic aortic stenosis. At select sites, a stress echocardiography sub-study also evaluated the performance of self expandable and balloon-expandable TAVR in this patient group, after exercise stress testing.

716 patients were enrolled in the trial, and were randomized on a 1:1 basis to receive TAVR with either a Medtronic self-expanding transcatheter aortic valve, or an Edwards balloon-expandable transcatheter heart valve.

Interview Questions:

  1. What is the reasoning behind this ancillary study?
  2. Could you tell us about the patient groups and data that were studied?
  3. What were your key findings?
  4. What is the implication of these findings on clinical practice?
  5. In short, what is your take-home message for clinicians?
  6. Where are the remaining knowledge gaps?

Recorded on-site at EuroPCR Congress, Paris, 2024.

Editor: Jordan Rance
Video Specialists: Dan Brent, 
Interviewer: Liam O'Neill


You must be to comment. If you are not registered, you can register here.